

INDEX

A

- Analysis
 construction 139–152
 map..... 143, 144
 sectioning..... 147, 151, 156
 slide staining..... 147
Antibody..... 57, 63, 72,
 110, 112, 114, 115, 117, 118, 120, 141, 148,
 155–159, 162–166, 171, 173–175, 178, 179, 184,
 185, 191, 192
Antigen retrieval..... 161, 165
Archived samples..... 78, 90, 94

B

- BeadArray..... 77–79, 82, 89
Beta cells
 function 16
Biomarker 1, 79, 94, 123, 147, 148
Bone marrow 56, 67, 72, 172, 174

C

- Cancer..... 1, 3, 9, 15, 35, 37, 47, 55–73,
 78, 90, 99, 110, 124, 127, 141, 143, 182, 198
Cell culture..... 4, 5, 17, 110–111, 170–171, 182, 183, 199,
 200, 207
Cell line..... 3, 17, 22, 31, 58, 71, 94,
 124, 127, 128, 134, 139–152, 179, 182, 186, 189,
 192–194, 200
Cell line array (CMA)..... 139–152
Circulating tumour cells (CTCs)..... 55–73
Clustering
 hierarchical 36–38, 43–46, 97, 148
 k-means 38, 45–47
CMA/TMA..... 139–152
Complementary DNA (cDNA) 4, 6–8, 10,
 16, 19, 20, 22–24, 27, 31, 32, 34, 44, 46, 78, 79,
 83, 84, 91, 92, 94, 96, 101–104
Conditioned medium (CM)..... 16–20, 22–25, 182, 183,
 186–188, 192–194
Cytoskeleton..... 164, 198, 200,
 206, 207

D

- DASL (cDNA-mediated annealing, selection, extension and
 ligation) assay..... 77–97
Data analysis..... 27–39, 41–52, 90, 91, 203
Densitometry..... 21–23, 114, 115, 118–119
Deoxynucleoside triphosphate (dNTP)..... 4, 6, 8,
 18, 20, 101–103, 105
Deoxyribonucleic acid (DNA)
 DNA chip (dCHIP)..... 33, 43–44
Differentially-expressed (DE) 32–35, 39,
 44–46, 49, 50, 92, 94, 124, 133

E

- Electrospray ionization (ESI-MS/MS)..... 124
Epithelial-mesenchymal transition (EMT)..... 197–208
Ethidium bromide 4, 6, 18, 21
Exosomes..... 181–194
Experiment
 double channel..... 29–30
 single channel 30–31
Experimental design 27–39, 45, 91, 202

F

- Fixatives
 acetone..... 166, 171, 178
 methanol..... 166, 171, 178
 methanol-acetone 178
Fluorescent resonance energy transfer (FRET)..... 3
Formalin-fixed paraffin-embedded (FFPE) 58, 71, 77–97

G

- Gel electrophoresis 4, 7, 10, 21, 111, 112, 123–136, 182
Gene expression analysis 1, 11, 27, 35,
 41, 43–48, 51, 55–73, 77–97, 99, 139–152,
 170, 182
Gene ontology (GO)..... 39, 43, 44, 48, 49

H

- HEK293T cells 3, 6, 8, 9
High-content analysis (HCA)..... 197–208

I

Image acquisition system.....42, 118, 191, 201–202
 Image analysis.....21, 32, 35, 42, 118, 120, 140, 148, 149, 176, 201
 Immunofluorescence 155–156, 172, 179, 199, 200
 Immunohistochemistry (IHC),.....58, 71, 140, 141, 144, 147–149, 155–166, 179
 Insulin-producing cells..... 16

M

Mass spectrometry..... 123–136, 182
 Matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-ToF MS).....124
 Microarray
 microarray data analysis system (MIDAS) 44–45
 microarray data manager (MADAM) 44
 significance analysis of microarrays (SAM)..... 45–46
 microRNA (miRNA)1, 99–107, 181–194
 Microscopy
 advanced microscopy 169–180
 atomic force microscopy (AFM)..... 197–208
 fluorescence microscopy..... 160, 169
 laser scanning confocal microscopy (LSCM) 169–180
 transmission electron microscopy (TEM) 185–186, 189, 192–193

MIN6

 MIN6 (H)16
 MIN6 (L).....16
 MIN6 B1..... 16, 17, 23
 Moloney murine leukemia virus (MMLV)..... 18, 20, 22
 mRNA.....1, 3, 7, 9, 10, 15–25, 27–39, 78, 79, 99, 181–194
 Multivesicular bodies (MVBs)..... 182

N

NanoDrop 18, 24, 103
 NIH–3T3..... 110, 113
 Normalisation.....2, 32–33, 42–47, 100
 Nucleic acids
 extracellular..... 15, 24

P

Pathway analysis 39, 44
 Peptide mass fingerprints (PMF) 124
 Peripheral blood mononuclear cells 68, 69
 Plasma..... 15, 24, 69, 171, 177, 179, 182, 187
 Polymerase chain reaction (PCR)
 Black Hole Quencher (BHQ) 2, 5, 8
 carboxy-X-rhodamine (ROX) 8

 multiplex..... 1–11, 182
 primers and probes design 4
 real-time/quantitative1–11, 102, 104–107
 reverse transcriptase (RT).....1, 3, 15–25, 182
 SybrGreen2
 Taq DNA polymerase enzyme..... 18, 100
 TaqMan probes..... 2, 3, 100
 threshold cycle (VIC).....2, 8, 11, 100
 Principal component analysis (PCA)..... 38–39, 45, 46
 Protein expression profiling..... 140
 Proteomics.....123, 124, 136, 182

Q

Quality control (QC)..... 4, 42–44, 78, 140, 148, 150

R

Receptor tyrosine kinase (RTKs)..... 109–120
 Replicates..... 25, 30, 31, 34, 91–93, 95
 Retro-orbital bleed 58, 68–69
 Ribonucleic acid (RNA) 1, 4–10, 15–20, 22–25, 28, 29, 31, 32, 58, 67, 69, 70, 73, 78, 79, 81, 82, 83, 90–97, 100–107, 182
 isolation
 cells5
 tissues.....6
 RNase-free
 DNase..... 10, 17, 20
 water..... 6, 17, 19, 20, 88, 101, 103, 106

S

Saliva..... 24, 124, 127, 182, 187
 SDS-polyacrylamide gel electrophoresis (SDS-PAGE),..... 110–112, 116, 119, 125, 126, 131, 132, 136, 184, 185
 Serum..... 4, 15–17, 24, 56, 106, 110, 112, 113, 119, 124, 127, 128, 162, 163, 165, 171–173, 175, 182–184, 186–189, 192–194, 199, 200, 206
 Software..... 4, 8, 18, 21, 28, 32, 41–52, 89, 96, 118, 120, 124, 126, 133, 135, 143, 176, 201, 202, 205–207
 Stem cell.....55, 56, 63, 67
 Surface markers 56, 65, 66

T

TaqMan low density microRNA array (TLDA) 101, 102, 105–107
 Thermal cycler.....2, 4, 8, 16, 18, 85
 Tissue arrayer 145, 150, 151
 Tissue microarray (TMA) 139–152
 Tumour initiating cell..... 55, 56, 60, 61, 63, 71

Two-dimensional difference gel
 electrophoresis (2D DIGE)124, 128, 129,
 131, 133, 134, 136

U

Urine..... 182, 186

W

Western blotting..... 109–120

X

Xenograft model.....61